To: All Healthcare Facilities

All Healthcare Professionals

Dear Colleagues,

HAAD is alerting all healthcare professionals on the recent decision made by Ministry of Health (MOH) to recall all available batches of:

**Diabetic 5mg Tablet (Glibenclamide)**, manufactured by the Kuwait Saudi Pharmaceutical Industries CO. (KSPICO).

The above action is undertaken subsequent to the Saudi Food and Drug Administration (SFDA) decision as the product was proven to be non-bioequivalent to the reference product (Daonil 5 mg Tablet).

Please note that this product is registered with the UAE Ministry of Health, and accordingly MOH cancelled its registration.

Based on the above, HAAD requires that the following immediate actions are taken:

1. **Drug agent (Inspire Drug Store)** to withdraw all available batches of the mentioned products from Abu Dhabi market.
2. Pharmacy managers to discontinue dispensing of the mentioned product and return the remaining stocks to the agent.
3. Healthcare Professionals to report any adverse reaction associated with the use of the above mentioned product to HAAD Pharmacovigilance program via:
   - Fax: 02 4193668
   - Email: pharmacovigilance@haad.ae

Your adherence is both anticipated and appreciated.

---

**Circular No. HRD/006/16**

February 22, 2016

Drug Recall: Diabetic 5mg Tablet

Send by Health Authority

HEALTH AUTHORITY

To: All Healthcare Facilities

All Healthcare Professionals

Dear Colleagues,

HAAD is alerting all healthcare professionals on the recent decision made by Ministry of Health (MOH) to recall all available batches of:

**Diabetic 5mg Tablet (Glibenclamide)**, manufactured by the Kuwait Saudi Pharmaceutical Industries CO. (KSPICO).

The above action is undertaken subsequent to the Saudi Food and Drug Administration (SFDA) decision as the product was proven to be non-bioequivalent to the reference product (Daonil 5 mg Tablet).

Please note that this product is registered with the UAE Ministry of Health, and accordingly MOH cancelled its registration.

Based on the above, HAAD requires that the following immediate actions are taken:

1. **Drug agent (Inspire Drug Store)** to withdraw all available batches of the mentioned products from Abu Dhabi market.
2. Pharmacy managers to discontinue dispensing of the mentioned product and return the remaining stocks to the agent.
3. Healthcare Professionals to report any adverse reaction associated with the use of the above mentioned product to HAAD Pharmacovigilance program via:
   - Fax: 02 4193668
   - Email: pharmacovigilance@haad.ae

Your adherence is both anticipated and appreciated.

---

**Circular No. HRD/006/16**

February 22, 2016

Drug Recall: Diabetic 5mg Tablet

Send by Health Authority

HEALTH AUTHORITY

To: All Healthcare Facilities

All Healthcare Professionals

Dear Colleagues,

HAAD is alerting all healthcare professionals on the recent decision made by Ministry of Health (MOH) to recall all available batches of:

**Diabetic 5mg Tablet (Glibenclamide)**, manufactured by the Kuwait Saudi Pharmaceutical Industries CO. (KSPICO).

The above action is undertaken subsequent to the Saudi Food and Drug Administration (SFDA) decision as the product was proven to be non-bioequivalent to the reference product (Daonil 5 mg Tablet).

Please note that this product is registered with the UAE Ministry of Health, and accordingly MOH cancelled its registration.

Based on the above, HAAD requires that the following immediate actions are taken:

1. **Drug agent (Inspire Drug Store)** to withdraw all available batches of the mentioned products from Abu Dhabi market.
2. Pharmacy managers to discontinue dispensing of the mentioned product and return the remaining stocks to the agent.
3. Healthcare Professionals to report any adverse reaction associated with the use of the above mentioned product to HAAD Pharmacovigilance program via:
   - Fax: 02 4193668
   - Email: pharmacovigilance@haad.ae

Your adherence is both anticipated and appreciated.

---

**Circular No. HRD/006/16**

February 22, 2016

Drug Recall: Diabetic 5mg Tablet

Send by Health Authority

HEALTH AUTHORITY

To: All Healthcare Facilities

All Healthcare Professionals

Dear Colleagues,

HAAD is alerting all healthcare professionals on the recent decision made by Ministry of Health (MOH) to recall all available batches of:

**Diabetic 5mg Tablet (Glibenclamide)**, manufactured by the Kuwait Saudi Pharmaceutical Industries CO. (KSPICO).

The above action is undertaken subsequent to the Saudi Food and Drug Administration (SFDA) decision as the product was proven to be non-bioequivalent to the reference product (Daonil 5 mg Tablet).

Please note that this product is registered with the UAE Ministry of Health, and accordingly MOH cancelled its registration.

Based on the above, HAAD requires that the following immediate actions are taken:

1. **Drug agent (Inspire Drug Store)** to withdraw all available batches of the mentioned products from Abu Dhabi market.
2. Pharmacy managers to discontinue dispensing of the mentioned product and return the remaining stocks to the agent.
3. Healthcare Professionals to report any adverse reaction associated with the use of the above mentioned product to HAAD Pharmacovigilance program via:
   - Fax: 02 4193668
   - Email: pharmacovigilance@haad.ae

Your adherence is both anticipated and appreciated.

---

**Circular No. HRD/006/16**

February 22, 2016

Drug Recall: Diabetic 5mg Tablet

Send by Health Authority

HEALTH AUTHORITY

To: All Healthcare Facilities

All Healthcare Professionals

Dear Colleagues,

HAAD is alerting all healthcare professionals on the recent decision made by Ministry of Health (MOH) to recall all available batches of:

**Diabetic 5mg Tablet (Glibenclamide)**, manufactured by the Kuwait Saudi Pharmaceutical Industries CO. (KSPICO).

The above action is undertaken subsequent to the Saudi Food and Drug Administration (SFDA) decision as the product was proven to be non-bioequivalent to the reference product (Daonil 5 mg Tablet).

Please note that this product is registered with the UAE Ministry of Health, and accordingly MOH cancelled its registration.

Based on the above, HAAD requires that the following immediate actions are taken:

1. **Drug agent (Inspire Drug Store)** to withdraw all available batches of the mentioned products from Abu Dhabi market.
2. Pharmacy managers to discontinue dispensing of the mentioned product and return the remaining stocks to the agent.
3. Healthcare Professionals to report any adverse reaction associated with the use of the above mentioned product to HAAD Pharmacovigilance program via:
   - Fax: 02 4193668
   - Email: pharmacovigilance@haad.ae

Your adherence is both anticipated and appreciated.

---

**Circular No. HRD/006/16**

February 22, 2016

Drug Recall: Diabetic 5mg Tablet

Send by Health Authority

HEALTH AUTHORITY

To: All Healthcare Facilities

All Healthcare Professionals

Dear Colleagues,

HAAD is alerting all healthcare professionals on the recent decision made by Ministry of Health (MOH) to recall all available batches of:

**Diabetic 5mg Tablet (Glibenclamide)**, manufactured by the Kuwait Saudi Pharmaceutical Industries CO. (KSPICO).

The above action is undertaken subsequent to the Saudi Food and Drug Administration (SFDA) decision as the product was proven to be non-bioequivalent to the reference product (Daonil 5 mg Tablet).

Please note that this product is registered with the UAE Ministry of Health, and accordingly MOH cancelled its registration.

Based on the above, HAAD requires that the following immediate actions are taken:

1. **Drug agent (Inspire Drug Store)** to withdraw all available batches of the mentioned products from Abu Dhabi market.
2. Pharmacy managers to discontinue dispensing of the mentioned product and return the remaining stocks to the agent.
3. Healthcare Professionals to report any adverse reaction associated with the use of the above mentioned product to HAAD Pharmacovigilance program via:
   - Fax: 02 4193668
   - Email: pharmacovigilance@haad.ae

Your adherence is both anticipated and appreciated.

---

**Circular No. HRD/006/16**

February 22, 2016

Drug Recall: Diabetic 5mg Tablet

Send by Health Authority

HEALTH AUTHORITY

To: All Healthcare Facilities

All Healthcare Professionals

Dear Colleagues,

HAAD is alerting all healthcare professionals on the recent decision made by Ministry of Health (MOH) to recall all available batches of:

**Diabetic 5mg Tablet (Glibenclamide)**, manufactured by the Kuwait Saudi Pharmaceutical Industries CO. (KSPICO).

The above action is undertaken subsequent to the Saudi Food and Drug Administration (SFDA) decision as the product was proven to be non-bioequivalent to the reference product (Daonil 5 mg Tablet).

Please note that this product is registered with the UAE Ministry of Health, and accordingly MOH cancelled its registration.

Based on the above, HAAD requires that the following immediate actions are taken:

1. **Drug agent (Inspire Drug Store)** to withdraw all available batches of the mentioned products from Abu Dhabi market.
2. Pharmacy managers to discontinue dispensing of the mentioned product and return the remaining stocks to the agent.
3. Healthcare Professionals to report any adverse reaction associated with the use of the above mentioned product to HAAD Pharmacovigilance program via:
   - Fax: 02 4193668
   - Email: pharmacovigilance@haad.ae

Your adherence is both anticipated and appreciated.